Stevanato Group Delivers 8% Revenue Growth for the Third Quarter of Fiscal 2026

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2026. Third Quarter of 2026 Highlights (comparisons to prior-year period) Revenue increased 8% to €326.1 million, and on an organic basis* revenue increased 8%. Revenue from high-value solutions represente.